Join

Compare · HOOK vs HUGE

HOOK vs HUGE

Side-by-side comparison of HOOKIPA Pharma Inc. (HOOK) and FSD Pharma Inc. (HUGE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both HOOK and HUGE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • HUGE is the larger of the two at $55.5M, about 1.4x HOOK ($41.0M).
  • HOOK has more recent analyst coverage (11 ratings vs 0 for HUGE).
MetricHOOKHUGE
Company
HOOKIPA Pharma Inc.
FSD Pharma Inc.
Price
$0.87-3.61%
$0.09-8.17%
Market cap
$41.0M
$55.5M
1M return
+0.00%
-
1Y return
-8.41%
-
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2019
News (4w)
0
0
Recent ratings
11
0
HOOK

HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

HUGE

FSD Pharma Inc.

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.

Latest HOOK

Latest HUGE